The estimated Net Worth of Leone D Patterson is at least $4.86 Milion dollars as of 9 February 2021. Ms. Patterson owns over 12,533 units of Adverum Biotechnologies Inc stock worth over $688,624 and over the last 8 years she sold ADVM stock worth over $1,337,304. In addition, she makes $2,830,320 as President at Adverum Biotechnologies Inc.
Leone has made over 6 trades of the Adverum Biotechnologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 12,533 units of ADVM stock worth $176,715 on 9 February 2021.
The largest trade she's ever made was selling 40,000 units of Adverum Biotechnologies Inc stock on 23 December 2019 worth over $428,800. On average, Leone trades about 5,714 units every 19 days since 2016. As of 9 February 2021 she still owns at least 97,955 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Ms. Patterson stock trades at the bottom of the page.
Leone D. Patterson CPA serves as President of the Company. Ms. Patterson was named our chief executive officer in October 2018. In connection with her promotion, our board appointed her as a member of the board. Ms. Patterson had been serving as the interim president and chief executive officer since May 2018, and served as our president during October 2018. She also served as our chief financial officer from June 2016 to April 2019. From March 2015 to June 2016, Ms. Patterson served as the chief financial officer of Diadexus, Inc., a diagnostics company, where she was responsible for overseeing the company’s finance function. Prior to that, Ms. Patterson was vice president and chief financial officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from June 2012 until it was acquired by Paratek Pharmaceuticals Inc. in October 2014, where she was responsible for overseeing the company’s finance function. From November 2010 to June 2012, Ms. Patterson served as vice president and global corporate controller of NetApp, Inc., a data management and storage company. From July 2007 to November 2010, Ms. Patterson was vice president of finance at Exelixis, Inc, a biopharmaceutical company. Before Exelixis, Ms. Patterson served as vice president of global business planning and analysis of the vaccines and diagnostics division of Novartis AG, a biopharmaceutical company, from April 2006 to July 2007. From 1999 to 2006, she held several positions, including vice President, corporate controller, at Chiron, a biotechnology company (now part of Novartis AG). From 1989 to 1999, Ms. Patterson worked in the audit practice of accounting firm KPMG, where she held various positions including Senior Manager. Ms. Patterson earned a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
As the President of Adverum Biotechnologies Inc, the total compensation of Leone Patterson at Adverum Biotechnologies Inc is $2,830,320. There are no executives at Adverum Biotechnologies Inc getting paid more.
Leone Patterson is 57, she's been the President of Adverum Biotechnologies Inc since 2020. There are 6 older and 11 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.
Leone's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard oraz Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: